Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Albert

Showing results (401-410 of 438) with videos related to

Pageof 44
Sort By:
Journal of Medicinal Chemistry|March 9, 2007
Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitorYujia Dai, Kresna Hartandi, Zhiqin Ji, et al.
Blood|December 25, 2015
Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescentsMarcin W Wlodarski, Shinsuke Hirabayashi, Victor Pastor, et al.
Journal of Medicinal Chemistry|September 27, 2017
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain InhibitorKeith F McDaniel, Le Wang, Todd Soltwedel, et al.
Nature|January 24, 2020
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancerEmily J Faivre, Keith F McDaniel, Daniel H Albert, et al.
Nature Genetics|August 18, 2014
JAGN1 deficiency causes aberrant myeloid cell homeostasis and congenital neutropeniaKaan Boztug, Päivi M Järvinen, Elisabeth Salzer, et al.
Journal of Medicinal Chemistry|April 4, 2017
Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain InhibitorsLe Wang, John K Pratt, Todd Soltwedel, et al.
Bone Marrow Transplantation|March 25, 2022
Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMTRafal Machowicz, Felipe Suarez, Wieslaw Wiktor-Jedrzejczak, et al.
Science Translational Medicine|March 20, 2015
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D Leverson, Darren C Phillips, Michael J Mitten, et al.
Blood Advances|June 20, 2025
Allogeneic hematopoietic stem cell transplantation for STAT3 hyper-IgE syndrome: a worldwide studyChristo Tsilifis, Johannes Raedler, Joanna Renke, et al.
Blood Advances|March 3, 2026
Outcome of Second Conditioned Allogeneic Stem Cell Transplant in Children with Non-SCID Inborn Errors of ImmunityZohreh Nademi, Su-Han Lum, Patrick Gilbert, et al.
Pageof 44

Showing results (401-410 of 438) with videos related to

Sort By:
Pageof 44
Journal of Medicinal Chemistry|March 9, 2007
Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitorYujia Dai, Kresna Hartandi, Zhiqin Ji, et al.
Blood|December 25, 2015
Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescentsMarcin W Wlodarski, Shinsuke Hirabayashi, Victor Pastor, et al.
Journal of Medicinal Chemistry|September 27, 2017
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain InhibitorKeith F McDaniel, Le Wang, Todd Soltwedel, et al.
Nature|January 24, 2020
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancerEmily J Faivre, Keith F McDaniel, Daniel H Albert, et al.
Nature Genetics|August 18, 2014
JAGN1 deficiency causes aberrant myeloid cell homeostasis and congenital neutropeniaKaan Boztug, Päivi M Järvinen, Elisabeth Salzer, et al.
Journal of Medicinal Chemistry|April 4, 2017
Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain InhibitorsLe Wang, John K Pratt, Todd Soltwedel, et al.
Bone Marrow Transplantation|March 25, 2022
Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMTRafal Machowicz, Felipe Suarez, Wieslaw Wiktor-Jedrzejczak, et al.
Science Translational Medicine|March 20, 2015
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D Leverson, Darren C Phillips, Michael J Mitten, et al.
Blood Advances|June 20, 2025
Allogeneic hematopoietic stem cell transplantation for STAT3 hyper-IgE syndrome: a worldwide studyChristo Tsilifis, Johannes Raedler, Joanna Renke, et al.
Blood Advances|March 3, 2026
Outcome of Second Conditioned Allogeneic Stem Cell Transplant in Children with Non-SCID Inborn Errors of ImmunityZohreh Nademi, Su-Han Lum, Patrick Gilbert, et al.
Pageof 44